Gefitinib plus chemotherapy versus gefitinib alone in untreated patients with EGFR-mutated non–small cell lung cancer and brain metastases (GAP Brain): An open-label, randomized, multicenter, phase 3 study.

Authors

Likun Chen

Department of Medical Oncology, Sun Yat-sen University Cancer Center, Guangzhou, China

Likun Chen , Xue Hou , Meichen Li , Guowu Wu , Weineng Feng , Jin Su , Honghua Jiang , Guanming Jiang , Baishen Zhang , Jing Chen , Zhixuan You

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Sign-In

Similar Posters

insert_chart_outlined

Poster

2015 ASCO Annual Meeting

bookmark_border

Intercalating and maintenance use of gefitinib plus chemotherapy versus chemotherapy alone in selected advanced NSCLC(ISCAN,CTONG-1102): A multicentre, open-label, randomised, phase 3 study.

First Author: Shun Lu

insert_chart_outlined

Poster

2014 ASCO Annual Meeting

bookmark_border

Final overall survival results of WJTOG 3405, a randomized phase 3 trial comparing gefitinib (G) with cisplatin plus docetaxel (CD) as the first-line treatment for patients with non-small cell lung cancer (NSCLC) harboring mutations of the epidermal growth factor receptor (EGFR).

First Author: Hiroshige Yoshioka

insert_chart_outlined

Poster

2014 ASCO Annual Meeting

bookmark_border

Continuation of afatinib beyond progression: Results of a randomized, open-label, phase III trial of afatanib plus paclitaxel (P) versus investigator’s choice chemotherapy (CT) in patients (pts) with metastatic non-small cell lung cancer (NSCLC) progressed on erlotinib/gefitinib (E/G) and afatanib—LUX-Lung 5 (LL5).

First Author: Martin H. Schuler

insert_chart_outlined

Poster

2013 ASCO Annual Meeting

bookmark_border

Phase III randomized, open label study (ARCHER 1050) of first-line dacomitinib (D) versus gefitinib (G) for advanced (adv) non-small cell lung cancer (NSCLC) in patients (pts) with epidermal growth factor receptor (EGFR) activating mutation(s).

First Author: Tony Mok